Mainz Biomed N.V (NASDAQ: MYNZ)’s stock price has decreased by -11.48 compared to its previous closing price of 1.83. However, the company has seen a -21.36% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-10 that BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V.
Is It Worth Investing in Mainz Biomed N.V (NASDAQ: MYNZ) Right Now?
MYNZ has 36-month beta value of 0.31. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for MYNZ is 3.69M, and currently, short sellers hold a 1.07% ratio of that float. The average trading volume of MYNZ on June 17, 2025 was 170.15K shares.
MYNZ’s Market Performance
MYNZ stock saw a decrease of -21.36% in the past week, with a monthly decline of -28.63% and a quarterly a decrease of -65.01%. The volatility ratio for the week is 4.92%, and the volatility levels for the last 30 days are 4.91% for Mainz Biomed N.V (MYNZ). The simple moving average for the last 20 days is -20.31% for MYNZ stock, with a simple moving average of -74.86% for the last 200 days.
Analysts’ Opinion of MYNZ
Many brokerage firms have already submitted their reports for MYNZ stocks, with Maxim Group repeating the rating for MYNZ by listing it as a “Buy.” The predicted price for MYNZ in the upcoming period, according to Maxim Group is $14 based on the research report published on February 14, 2025 of the current year 2025.
MYNZ Trading at -37.80% from the 50-Day Moving Average
After a stumble in the market that brought MYNZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.90% of loss for the given period.
Stock Fundamentals for MYNZ
Current profitability levels for the company are sitting at:
- -20.91 for the present operating margin
- 0.64 for the gross margin
The net margin for Mainz Biomed N.V stands at -24.22. The total capital return value is set at -2.57.
Based on Mainz Biomed N.V (MYNZ), the company’s capital structure generated 0.35 points at debt to capital in total, while cash flow to debt ratio is standing at -5.22. The debt to equity ratio resting at 0.54. The interest coverage ratio of the stock is -17.39.
Currently, EBITDA for the company is -19.56 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 3.6. The receivables turnover for the company is 4.18for trailing twelve months and the total asset turnover is 0.07.
Conclusion
To put it simply, Mainz Biomed N.V (MYNZ) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
